Exelixis initiates trial for XB628 and zanzalintinib in advanced solid tumors
Exelixis is conducting a study to evaluate XB628 alone and with zanzalintinib in patients with recurrent advanced or metastatic solid tumors.
Asset / Drug
Drug and asset intelligence for Exelixis with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.